BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 25878112)

  • 21. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.
    Misra A; Gleeson E; Wang W; Ye C; Zhou P; Kimata JT
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells.
    Falkenhagen A; Ameli M; Asad S; Read SE; Joshi S
    Gene Ther; 2014 Feb; 21(2):175-87. PubMed ID: 24305417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV.
    Carrillo MA; Zhen A; Zack JA; Kitchen SG
    Transl Res; 2017 Sep; 187():83-92. PubMed ID: 28755872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
    Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
    Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.
    Espy N; Pacheco B; Sodroski J
    Virology; 2017 Aug; 508():90-107. PubMed ID: 28521215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
    Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
    Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide.
    Jiang A; Fisher H; Pomerantz RJ; Dornburg R
    Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120.
    Bitton N; Verrier F; Debré P; Gorochov G
    Eur J Immunol; 1998 Dec; 28(12):4177-87. PubMed ID: 9862354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.
    Zhang MY; Borges AR; Ptak RG; Wang Y; Dimitrov AS; Alam SM; Wieczorek L; Bouma P; Fouts T; Jiang S; Polonis VR; Haynes BF; Quinnan GV; Montefiori DC; Dimitrov DS
    MAbs; 2010; 2(3):266-74. PubMed ID: 20305395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes.
    Liegler TJ; Stites DP
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):340-8. PubMed ID: 7907660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
    Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
    PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.
    Chen W; Xiao X; Wang Y; Zhu Z; Dimitrov DS
    Antiviral Res; 2010 Oct; 88(1):107-15. PubMed ID: 20709110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. eCD4-Ig Variants That More Potently Neutralize HIV-1.
    Fetzer I; Gardner MR; Davis-Gardner ME; Prasad NR; Alfant B; Weber JA; Farzan M
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection.
    Briant L; Coudronnière N; Robert-Hebmann V; Benkirane M; Devaux C
    J Immunol; 1996 May; 156(10):3994-4004. PubMed ID: 8621941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site.
    Dowd CS; Leavitt S; Babcock G; Godillot AP; Van Ryk D; Canziani GA; Sodroski J; Freire E; Chaiken IM
    Biochemistry; 2002 Jun; 41(22):7038-46. PubMed ID: 12033937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.